the Company may issue and sell from time to time, at its option, up to an aggregate of $80 million of shares of the Company’s common stock, par value $0.00001 per share, through Jefferies, acting as …
Our license agreement with Anacor requires us to satisfy diligence requirements, including using commercially reasonable efforts to develop and commercialize products.
the Company terminated the Sales Agreement (the “TD Cowen Sales Agreement”), dated April 6, 2023, that the Company previously entered into with Cowen and Company, LLC, which was assigned to TD Securi…
the Company terminated the Sales Agreement (the “TD Cowen Sales Agreement”), dated April 6, 2023, that the Company previously entered into with Cowen and Company, LLC, which was assigned to TD Securi…
. As a result, the Company did no t record any research and development expense—related party in the condensed statements of operations for the three months ended March 31, 2026 and 2025. 17 Brii Bio…
AN2 Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ANTX-DEBT-7775
Warrants outstanding: 1e-05
90%
xbrl warrant detail from xbrl 2025-06-30.
ANTX-DEBT-7776
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
AN2 Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for AN2 Therapeutics, Inc..
AN2 Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ANTX-OWNER-VIVO-CAPITAL-LLC
Vivo Capital, LLC
90%
13F overlay lists Vivo Capital, LLC as top holder; 52 tracked holders.
AN2 Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
